Addition of IFN-α to Treatment of Malignant Brain Tumors
Despite many attempts to improve the survival after surgery of patients with malignant astrocytoma the prognosis is poor. We have used natural IFN-α in 16 patients with malignant astrocytoma treated between 1987 and 1990; 6 for recurrent tumors. Radiation therapy was given in 2 Gy fractions daily to...
Gespeichert in:
| Veröffentlicht in: | Acta oncologica 1994, Vol.33 (6), p.651-654 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 654 |
|---|---|
| container_issue | 6 |
| container_start_page | 651 |
| container_title | Acta oncologica |
| container_volume | 33 |
| creator | Jereb, Berta Petri -grabnar, Gabrijela Klun, Boris Lamovec, Janez Škrbec, Miha Šooš, Evgen |
| description | Despite many attempts to improve the survival after surgery of patients with malignant astrocytoma the prognosis is poor. We have used natural IFN-α in 16 patients with malignant astrocytoma treated between 1987 and 1990; 6 for recurrent tumors. Radiation therapy was given in 2 Gy fractions daily to a total dose of 50 Gy in the tumor area, 5 fractions per week and IFN twice per week, cisplatinum 60 mg/m2 i.v. every second week and vincristine 2 mg every week in 12-h i.v. infusions. Eight patients were reoperated when clinical deterioration suggested recurrent tumor; histological examination showed no residual tumor in 7 of them. Of these 8 patients 3 are alive and well, 2 of them after more than 5 years. The study suggests that malignant astrocytoma can be successfully eradicated with surgery, irradiation, IFN-α and chemotherapy. The treatment had, however, unacceptably high neurotoxicity. Earlier removal of the tumor necrosis, before clinical deterioration, could possibly diminish the high complication rate and consequently improve survival. |
| doi_str_mv | 10.3109/02841869409121777 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_02841869409121777</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>7946443</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-bbcb52e1d938284de836090fb8aea1ca0108b003026a15972b7b9d1f494e02813</originalsourceid><addsrcrecordid>eNp9UEFOwzAQtBColMIDOCDlA4Fd24ljcSoVhUoFLkXqLVonDk3VxJWTHngWH-FNuGrFBYnTand2RjPD2DXCrUDQd8AziVmqJWjkqJQ6YUNME4w5T5enbLjH4_CwPGcXXbcGAC5UMmADpWUqpRgyPS7Luq9dG7kqmk1f4--vqHfRwlvqG9v2-_MLbeqPlsLy4Kluo8Wucb67ZGcVbTp7dZwj9j59XEye4_nb02wynseF0NjHxhQm4RZLLbLgprSZSEFDZTKyhAUBQmYABPCUMNGKG2V0iZXU0gb7KEYMD7qFd13nbZVvfd2Q_8wR8n0L-Z8WAufmwNnuTGPLX8YxdsDvD3jdVs43tLK06VcFeZuv3c63Ic8_6j_SrWi6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Addition of IFN-α to Treatment of Malignant Brain Tumors</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Taylor & Francis Journals Complete</source><creator>Jereb, Berta ; Petri -grabnar, Gabrijela ; Klun, Boris ; Lamovec, Janez ; Škrbec, Miha ; Šooš, Evgen</creator><creatorcontrib>Jereb, Berta ; Petri -grabnar, Gabrijela ; Klun, Boris ; Lamovec, Janez ; Škrbec, Miha ; Šooš, Evgen</creatorcontrib><description>Despite many attempts to improve the survival after surgery of patients with malignant astrocytoma the prognosis is poor. We have used natural IFN-α in 16 patients with malignant astrocytoma treated between 1987 and 1990; 6 for recurrent tumors. Radiation therapy was given in 2 Gy fractions daily to a total dose of 50 Gy in the tumor area, 5 fractions per week and IFN twice per week, cisplatinum 60 mg/m2 i.v. every second week and vincristine 2 mg every week in 12-h i.v. infusions. Eight patients were reoperated when clinical deterioration suggested recurrent tumor; histological examination showed no residual tumor in 7 of them. Of these 8 patients 3 are alive and well, 2 of them after more than 5 years. The study suggests that malignant astrocytoma can be successfully eradicated with surgery, irradiation, IFN-α and chemotherapy. The treatment had, however, unacceptably high neurotoxicity. Earlier removal of the tumor necrosis, before clinical deterioration, could possibly diminish the high complication rate and consequently improve survival.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.3109/02841869409121777</identifier><identifier>PMID: 7946443</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Adult ; Aged ; Astrocytoma - therapy ; Brain Neoplasms - therapy ; Combined Modality Therapy ; Female ; Glioblastoma - therapy ; Humans ; Interferon-alpha - therapeutic use ; Male ; Middle Aged ; Neoplasm Recurrence, Local - therapy ; Survival Analysis ; Treatment Outcome</subject><ispartof>Acta oncologica, 1994, Vol.33 (6), p.651-654</ispartof><rights>1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1994</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-bbcb52e1d938284de836090fb8aea1ca0108b003026a15972b7b9d1f494e02813</citedby><cites>FETCH-LOGICAL-c391t-bbcb52e1d938284de836090fb8aea1ca0108b003026a15972b7b9d1f494e02813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/02841869409121777$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/02841869409121777$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,61221,61402</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7946443$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jereb, Berta</creatorcontrib><creatorcontrib>Petri -grabnar, Gabrijela</creatorcontrib><creatorcontrib>Klun, Boris</creatorcontrib><creatorcontrib>Lamovec, Janez</creatorcontrib><creatorcontrib>Škrbec, Miha</creatorcontrib><creatorcontrib>Šooš, Evgen</creatorcontrib><title>Addition of IFN-α to Treatment of Malignant Brain Tumors</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>Despite many attempts to improve the survival after surgery of patients with malignant astrocytoma the prognosis is poor. We have used natural IFN-α in 16 patients with malignant astrocytoma treated between 1987 and 1990; 6 for recurrent tumors. Radiation therapy was given in 2 Gy fractions daily to a total dose of 50 Gy in the tumor area, 5 fractions per week and IFN twice per week, cisplatinum 60 mg/m2 i.v. every second week and vincristine 2 mg every week in 12-h i.v. infusions. Eight patients were reoperated when clinical deterioration suggested recurrent tumor; histological examination showed no residual tumor in 7 of them. Of these 8 patients 3 are alive and well, 2 of them after more than 5 years. The study suggests that malignant astrocytoma can be successfully eradicated with surgery, irradiation, IFN-α and chemotherapy. The treatment had, however, unacceptably high neurotoxicity. Earlier removal of the tumor necrosis, before clinical deterioration, could possibly diminish the high complication rate and consequently improve survival.</description><subject>Adult</subject><subject>Aged</subject><subject>Astrocytoma - therapy</subject><subject>Brain Neoplasms - therapy</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Glioblastoma - therapy</subject><subject>Humans</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UEFOwzAQtBColMIDOCDlA4Fd24ljcSoVhUoFLkXqLVonDk3VxJWTHngWH-FNuGrFBYnTand2RjPD2DXCrUDQd8AziVmqJWjkqJQ6YUNME4w5T5enbLjH4_CwPGcXXbcGAC5UMmADpWUqpRgyPS7Luq9dG7kqmk1f4--vqHfRwlvqG9v2-_MLbeqPlsLy4Kluo8Wucb67ZGcVbTp7dZwj9j59XEye4_nb02wynseF0NjHxhQm4RZLLbLgprSZSEFDZTKyhAUBQmYABPCUMNGKG2V0iZXU0gb7KEYMD7qFd13nbZVvfd2Q_8wR8n0L-Z8WAufmwNnuTGPLX8YxdsDvD3jdVs43tLK06VcFeZuv3c63Ic8_6j_SrWi6</recordid><startdate>1994</startdate><enddate>1994</enddate><creator>Jereb, Berta</creator><creator>Petri -grabnar, Gabrijela</creator><creator>Klun, Boris</creator><creator>Lamovec, Janez</creator><creator>Škrbec, Miha</creator><creator>Šooš, Evgen</creator><general>Informa UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1994</creationdate><title>Addition of IFN-α to Treatment of Malignant Brain Tumors</title><author>Jereb, Berta ; Petri -grabnar, Gabrijela ; Klun, Boris ; Lamovec, Janez ; Škrbec, Miha ; Šooš, Evgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-bbcb52e1d938284de836090fb8aea1ca0108b003026a15972b7b9d1f494e02813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Astrocytoma - therapy</topic><topic>Brain Neoplasms - therapy</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Glioblastoma - therapy</topic><topic>Humans</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jereb, Berta</creatorcontrib><creatorcontrib>Petri -grabnar, Gabrijela</creatorcontrib><creatorcontrib>Klun, Boris</creatorcontrib><creatorcontrib>Lamovec, Janez</creatorcontrib><creatorcontrib>Škrbec, Miha</creatorcontrib><creatorcontrib>Šooš, Evgen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jereb, Berta</au><au>Petri -grabnar, Gabrijela</au><au>Klun, Boris</au><au>Lamovec, Janez</au><au>Škrbec, Miha</au><au>Šooš, Evgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Addition of IFN-α to Treatment of Malignant Brain Tumors</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>1994</date><risdate>1994</risdate><volume>33</volume><issue>6</issue><spage>651</spage><epage>654</epage><pages>651-654</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><abstract>Despite many attempts to improve the survival after surgery of patients with malignant astrocytoma the prognosis is poor. We have used natural IFN-α in 16 patients with malignant astrocytoma treated between 1987 and 1990; 6 for recurrent tumors. Radiation therapy was given in 2 Gy fractions daily to a total dose of 50 Gy in the tumor area, 5 fractions per week and IFN twice per week, cisplatinum 60 mg/m2 i.v. every second week and vincristine 2 mg every week in 12-h i.v. infusions. Eight patients were reoperated when clinical deterioration suggested recurrent tumor; histological examination showed no residual tumor in 7 of them. Of these 8 patients 3 are alive and well, 2 of them after more than 5 years. The study suggests that malignant astrocytoma can be successfully eradicated with surgery, irradiation, IFN-α and chemotherapy. The treatment had, however, unacceptably high neurotoxicity. Earlier removal of the tumor necrosis, before clinical deterioration, could possibly diminish the high complication rate and consequently improve survival.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>7946443</pmid><doi>10.3109/02841869409121777</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0284-186X |
| ispartof | Acta oncologica, 1994, Vol.33 (6), p.651-654 |
| issn | 0284-186X 1651-226X |
| language | eng |
| recordid | cdi_crossref_primary_10_3109_02841869409121777 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Taylor & Francis Journals Complete |
| subjects | Adult Aged Astrocytoma - therapy Brain Neoplasms - therapy Combined Modality Therapy Female Glioblastoma - therapy Humans Interferon-alpha - therapeutic use Male Middle Aged Neoplasm Recurrence, Local - therapy Survival Analysis Treatment Outcome |
| title | Addition of IFN-α to Treatment of Malignant Brain Tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T20%3A20%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Addition%20of%20IFN-%CE%B1%20to%20Treatment%20of%20Malignant%20Brain%20Tumors&rft.jtitle=Acta%20oncologica&rft.au=Jereb,%20Berta&rft.date=1994&rft.volume=33&rft.issue=6&rft.spage=651&rft.epage=654&rft.pages=651-654&rft.issn=0284-186X&rft.eissn=1651-226X&rft_id=info:doi/10.3109/02841869409121777&rft_dat=%3Cpubmed_cross%3E7946443%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/7946443&rfr_iscdi=true |